The Nasdaq Stock Market ended the session with Moderna rising 4.59% to $159.52 on Monday while the Nasdaq Stock Market jumped 0.45% to $12,520.00.

Moderna today’s close was $159.52, 11.90% under its 52-week high of $178.50.

Moderna’s Sales

Moderna’s sales growth is 1428.1% for the current quarter and 13065.3% for the next. The company’s growth estimates for the present quarter is a negative 48.6% and positive 565.7% for the next.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna’s Stock Top and Bottom Yearly Value

Moderna’s stock is valued at $159.52 at 20:58 EST, way under its 52-week high of $178.50 and way higher than its 52-week low of $17.68.

Moderna’s Moving Average

Moderna’s worth is way above its 50-day moving average of $91.57 and way above its 200-day moving average of $73.81.

Previous days news about Moderna

Early bet on Moderna sees top european fund gain 65% this year. According to Bloomberg Quint on Mon Dec 7, “A Baillie Gifford & Co. health care fund run by an all-female team has surged past peers to a 65% gain this year, largely thanks to a far-sighted bet on medical stock Moderna Inc.”

Moderna shares rally as Canada doubles vaccine order. According to MarketWatch on Mon Dec 7, “Shares of Moderna Inc. rallied 1.3% in morning trading Monday, after the biotechnology company said the Canadian government has doubled its order commitment for the company’s COVID-19 vaccine candidate.”

Moderna, Pfizer won’t attend white house summit on vaccines. According to Bloomberg Quint on Mon Dec 7, “The two pharmaceutical companies closest to gaining U.S. clearance for a Covid-19 vaccine won’t attend a planned White House summit intended to build confidence in the shots.”


Please enter your comment!
Please enter your name here